膀胱癌患者生活质量:一项患者报告结局的横断面调查
该研究基于英国国家癌症登记数据,对诊断后1–10年的膀胱癌患者进行邮寄问卷调查,共完成1796份(应答率55%)。结果显示,膀胱癌患者健康相关生活质量(HRQOL)与疾病分期和治疗方式关系不大,但性功能和财务困难问题突出,且总体HRQOL差于结直肠癌、前列腺癌患者及一般人群。
要点
- 膀胱癌患者HRQOL与分期和治疗方式无关,年龄和合并症影响更大。
- 男性性功能问题常见,年轻和根治性治疗者更明显。
- 年轻患者财务困难更突出,总体HRQOL差于其他盆腔肿瘤。
核心结论
- 膀胱癌治疗后HRQOL相对独立于疾病分期、治疗和多模式治疗。
- 性功能和财务毒性问题突出,且HRQOL差于其他盆腔肿瘤。
研究设计与样本
- 横断面调查,覆盖英格兰10%人口,通过国家癌症登记数据识别诊断后1–10年患者。
- 邮寄问卷包含通用HRQOL和膀胱癌特异性结局指标,共完成1796份(应答率55%)。
主要发现
- 69%的参与者在任何EQ-5D维度报告至少一个问题。
- 年龄/性别调整后通用HRQOL在各分期和治疗组间相似,但问题随年龄增长而增加(<65岁67% [95%CI: 61-74] vs 85+岁84% [95%CI: 81-89],p=0.016)。
- 长期疾病状况影响显著(无疾病53% [95%CI: 48-58] vs 超过四种疾病94% [95%CI: 90-97],p<0.001)。
- 男性性功能问题常见,随年轻年龄和根治性治疗而增加。
- 年轻参与者(<65岁)财务困难评分更高(平均20 [95%CI: 16-25] vs 85+岁6.8 [4.5-9.2],p<0.001)。
临床怎么用
- 临床应关注膀胱癌患者的性功能和财务困难问题,尤其是年轻和接受根治性治疗者。
- 评估HRQOL时需考虑年龄和合并症,而非仅关注肿瘤分期和治疗方式。
局限性
- 横断面设计无法推断因果关系。
- 应答率55%,可能存在无应答偏倚。
- 治疗未知患者35例(1.9%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about health-related quality of life (HRQOL) following treatment for bladder cancer (BC). OBJECTIVE: To determine this, we undertook a cross-sectional survey covering 10% of the English population. DESIGN, SETTING, AND PARTICIPANTS: Participants 1-10 yr from diagnosis were identified through national cancer registration data. INTERVENTION: A postal survey was administered containing generic HRQOL and BC-specific outcome measures. Findings were compared with those of the general population and other pelvic cancer patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Generic HRQOL was measured using five-level EQ-5D (EQ-5D-5L) and European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30. BC-specific outcomes were derived from EORTC QLQ-BLM30 and EORTC QLQ-NMIBC24. RESULTS AND LIMITATIONS: A total of 1796 surveys were completed (response rate 55%), including 868 (48%) patients with non-muscle-invasive BC, 893 (50%) patients who received radiotherapy or radical cystectomy, and 35 (1.9%) patients for whom treatment was unknown. Most (69%) of the participants reported at least one problem in any EQ-5D dimension. Age/sex-adjusted generic HRQOL outcomes were similar across all stages and treatment groups, whilst problems increased with age (problems in one or more EQ-5D dimensions: <65 yr [67% {95% confidence interval or CI: 61-74}] vs 85+ yr [84% {95% CI: 81-89}], p = 0.016) and long-term conditions (no conditions [53% {95% CI: 48-58}] vs more than four conditions [94% {95% CI: 90-97}], p < 0.001). Sexual problems were reported commonly in men, increasing with younger age and radical treatment. Younger participants (under 65 yr) reported more financial difficulties (mean score 20 [95% CI: 16-25]) than those aged 85+ yr (6.8 [4.5-9.2], p < 0.001). HRQOL for BC patients (for comparison, males with problems in one or more EQ-5D dimensions 69% [95% CI: 66-72]) was significantly worse than what has been found after colorectal and prostate cancers and in the general population (51% [95% CI: 48-53], all p < 0.05). CONCLUSIONS: HRQOL following BC appears to be relatively independent of disease stage, treatment, and multimodal care. Issues are reported with sexual function and financial toxicity. HRQOL after BC is worse than that after other pelvic cancers. PATIENT SUMMARY: Patients living with bladder cancer often have reduced quality of life, which may be worse than that for other common pelvic cancer patients. Age and other illnesses appear to be more important in determining this quality of life than the treatments received. Many men complain of sexual problems. Younger patients have financial worries.
引用
- Catto JWF, Downing A, Mason S, et al. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. Eur Urol. 2021. PMID: 33581875. doi:10.1016/j.eururo.2021.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。